Serinus Biosciences is an AI drug discovery company designing small molecule disrupters for protein-protein interactions (PPI). Our proprietary proteome-wide interface energetics map transforms any natural protein ligand into a small molecule binding opportunity. With over 60% of the proteome estimated to have binding hot loops at small molecule scale, we are geared to reveal orthosteric docking sites in tens of thousands of previously undruggable targets. Together with our PPI-specific generative AI engine, we design potent and synthetically accessible interface binding hits in months instead of years.
Company Details
- Employees
- 5
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.serinus.bio
Serinus Biosciences Questions
Serinus Biosciences's website is https://www.serinus.bio
Serinus Biosciences's LinkedIn profile is https://www.linkedin.com/company/serinus-biosciences
Serinus Biosciences has
5 employees.
View email and phone details for 5
employees at Serinus Biosciences.
Serinus Biosciences's industry is
Biotechnology Research
Serinus Biosciences's top competitors are
Ordaos Bio,
Volastra Therapeutics,
Nilo Therapeutics,
Orbits Oncology,
Prism.bio,
Output Biosciences,
Simcare Ai (Yc S24),
Aperture Bio,
Formation Bio,
Ascent Bio.
Serinus Biosciences's categories are Biotechnology Research
Serinus Biosciences's founding year is 2022
